Repros Therapeutics Inc. (Nasdaq: RPRX) reported positive results from a study of its secondary hypogonadism treatment Androxal and announced that the Food and Drug Administration granted a Type B Pre-NDA meeting to discuss the company's planned New Drug Application for Androxal. The stock price soared $1.52 to close at $10.48.